دورية
Tabelecleucel for EBV+PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol
| العنوان: | Tabelecleucel for EBV+PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol |
|---|---|
| المؤلفون: | Nikiforow, Sarah, Whangbo, Jennifer S., Reshef, Ran, Tsai, Donald E., Bunin, Nancy, Abu-Arja, Rolla, Mahadeo, Kris Michael, Weng, Wen-Kai, Van Besien, Koen, Loeb, David, Nasta, Sunita Dwivedy, Nemecek, Eneida R., Zhao, Weizhi, Sun, Yan, Galderisi, Faith, Wahlstrom, Justin, Mehta, Aditi, Gamelin, Laurence, Dinavahi, Rajani, Prockop, Susan |
| المصدر: | Blood Advances; June 2024, Vol. 8 Issue: 12 p3001-3012, 12p |
| مستخلص: | •In this R/R population with high unmet need, patients responding to tabelecleucel demonstrated a clinically meaningful survival benefit.•Tabelecleucel has a favorable safety profile and shows durable clinical benefit in R/R EBV+PTLD after HCT or SOT. |
| قاعدة البيانات: | Supplemental Index |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 24739529 24739537 |
|---|---|
| DOI: | 10.1182/bloodadvances.2023011626 |